MSB 5.24% $1.11 mesoblast limited

Ann: Remestemcel-L Improves Survival in High-Risk Acute GvHD, page-78

  1. 540 Posts.
    lightbulb Created with Sketch. 172
    What are your thoughts that they maybe able to leverage off the ARDS RCT?

    I kinda remember SI mentioning that the ARDS trial have been done in a manner to help support aGVHD.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.